John Sundy
Direktor/Vorstandsmitglied bei SANOFI
Profil
John Sundy is currently an Independent Director at Sanofi and a Director at Neutrolis, Inc. Previously, he held the position of Senior Vice President at Gilead Sciences, Inc. from 2014 to 2020.
He also served as an Associate Professor at Duke University and Duke-NUS Graduate Medical School Singapore from 2006 to 2014.
Additionally, he was the Chief Medical Officer at Pandion Therapeutics, Inc. Dr. Sundy completed his undergraduate degree at Bucknell University and obtained doctorate degrees from Drexel University College of Medicine and Hahnemann University.
Aktive Positionen von John Sundy
| Unternehmen | Position | Beginn |
|---|---|---|
| SANOFI | Direktor/Vorstandsmitglied | 30.04.2024 |
Neutrolis, Inc.
 Neutrolis, Inc. Pharmaceuticals: MajorHealth Technology Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von John Sundy
| Unternehmen | Position | Ende |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01.04.2020 |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | Corporate Officer/Principal | 01.01.2014 |
| Duke-NUS Graduate Medical School Singapore | Corporate Officer/Principal | 01.01.2014 |
| PANDION THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von John Sundy
| Bucknell University | Undergraduate Degree |
| Drexel University College of Medicine | Doctorate Degree |
| Hahnemann University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| SANOFI | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Pandion Therapeutics, Inc.
 Pandion Therapeutics, Inc. BiotechnologyHealth Technology Pandion Therapeutics, Inc. is a clinical stage biopharmaceutical company. It develops Therapeutic Autoimmune reguLatOry proteiN (TALON) drug design and discovery platform, which employ a modular approach to create a pipeline of product candidates using immunomodulatory effector modules that act at known control nodes within the immune network. The company was founded by Dr. Joanne Viney on September 19, 2016 and is headquartered in Watertown, MA. | Health Technology |
Neutrolis, Inc.
Neutrolis, Inc. Pharmaceuticals: MajorHealth Technology Neutrolis, Inc. is a biotechnology company located in North Cambridge, MA. The company develops first-in-class therapies that target neutrophils and their pathogenic products, including nets. Neutrolis proprietary platform, Chromatinase™, is based on the naturally occurring enzymes that break down the extracellular chromatin that form nets. The company's lead product, NTR-441, is a patented, first-in-class, engineered DNASE1L3 analog with potential application in COVID-19, ARDS, lupus, rheumatoid arthritis, systemic sclerosis, and other net-mediated diseases. Neutrolis has received two competitive LabCentral Golden Ticket awards from Pfizer and Bristol-Myers Squibb. The company was founded by Abdul Hakkim and Toby Fox. Toby Fox has been the CEO since incorporation. | Health Technology |
